| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/18/2006 | US7030218 Extending ligation technique to peptides, polypeptides, other polymers and other molecules via an amide bond; used in the synthesis of optionally polymer-modified, synthetic bioactive proteins, and of pharmaceutical compositions |
| 04/18/2006 | US7030160 An agonist as beta-3 adrenergic receptors; chemical intermediates preparing through decyclization, hydroxylation; for treating gastrointestinal diseases, obesity, diabetics, psychotropic agents, nervous system disorders |
| 04/18/2006 | US7030151 Micronized amorphous form for better bioavailability; hypercholesterolemia, hyperlipidemia |
| 04/18/2006 | US7030147 Synergistic mixture; antiproliferative agents; side effect reduction |
| 04/18/2006 | US7030144 Central nervous system disorders |
| 04/18/2006 | US7030139 Compounds |
| 04/18/2006 | US7030138 Benzamidine derivatives |
| 04/18/2006 | US7030135 A sulfonylamino-tetrahydro(1,3)thiazolo(5,4-c)pyridinyl or benzothiazole derivatives, for treating diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, osteoporosis, tuberculosis, dementia |
| 04/18/2006 | US7030128 Imidazo-pyrimidine derivatives as ligands for GABA receptors |
| 04/18/2006 | US7030124 Method of treating depression with delta receptor agonist compounds |
| 04/18/2006 | US7030123 Indole derivatives with vascular damaging activity |
| 04/18/2006 | US7030120 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same |
| 04/18/2006 | US7030110 Cyclic oxyguanidine pyrazinones as protease inhibitors |
| 04/18/2006 | US7030107 nitrogen compounds such as 5-[3,5-bis(trifluoromethyl)benzyl]-6-oxo-7-phenyl-9-[4-(pyrrolidine-1-yl)piperidine-1-yl]-2,3,4,5-tetrahydro-6H-pyrido[2,3-b][1,5]oxazocine, used as neurokinin inhibitors for prophylaxis of urogenital disorders; side effect reduction |
| 04/18/2006 | US7030103 Such as ((benzylsulfonylamino)methyl)-phosphonic acid mono-(4-nitrophenyl)ester sodium salt; for treating bacterial antibiotic resistance |
| 04/18/2006 | US7030087 A water-soluble polypeptide having hydrophobic side chains, for use as bactericides treating infections, detoxification of endotoxin, cell antiproliferative agents, antagonist of tumor necrosis factor |
| 04/18/2006 | US7030086 Stabilized liquid polypeptide-containing pharmaceutical compositions |
| 04/18/2006 | US7029914 DNA encoding SNORF36 receptors |
| 04/18/2006 | US7029906 For reducing carbonyl stress in peritoneal dialysate |
| 04/18/2006 | US7029898 Comprises chimeric polypeptide with hydrolase and mitogen activated protein kinase activity for diagnosis and treatment of cell proliferation and differentiation disorders |
| 04/18/2006 | US7029877 binding protease thrombin to phosphoethanolamine binding protein |
| 04/18/2006 | US7029713 Peptide extract of lupine and pharmaceutical or cosmetic or nutritional composition comprising the same |
| 04/18/2006 | US7029710 For inhibiting amyloid formation, deposition, accumulation, or persistence, or amyloid protein-amyloid protein interactions, amyloid-proteoglycan interactions, amyloid-PG/GAG interactions and/or amyloid-glycosaminoglycan interactions |
| 04/18/2006 | US7029696 Delivery and activation through liposome incorporation of diaminocyclohexane platinum(II) complexes |
| 04/18/2006 | US7029674 contacting an immune cell with an agent that modulates the interaction between PD-1 and a PD-1 ligand (e.g., soluble forms of PD-1 or PD-1 ligand or antibodies to PD-1); inhibits signaling via PD-1 |
| 04/18/2006 | US7029666 Uses for non-autologous mesenchymal stem cells |
| 04/18/2006 | US7029658 Delivery of antidepressants through an inhalation route |
| 04/18/2006 | US7029654 anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage |
| 04/18/2006 | CA2409059C Stabilized aqueous suspensions for parenteral use |
| 04/13/2006 | WO2006038738A1 Receptor function regulating agent |
| 04/13/2006 | WO2006038729A1 Mutated amyloid protein |
| 04/13/2006 | WO2006038721A1 External preparation |
| 04/13/2006 | WO2006038719A1 Phosphonic acid derivative and therapeutic agent for disease in which high phosphate level in blood participates |
| 04/13/2006 | WO2006038680A1 2-arylcarboxamide-nitrogeneous heterocycle compound |
| 04/13/2006 | WO2006038656A1 Allergy suppressant |
| 04/13/2006 | WO2006038606A1 Biaryl derivative |
| 04/13/2006 | WO2006038596A1 Pharmaceutical composition for xerophthalmia and xerostomia treatment |
| 04/13/2006 | WO2006038594A1 N-type calcium channel inhibitor |
| 04/13/2006 | WO2006038527A1 Antitumor immunostimulant containing extract from pleurotus cornucopiae as active ingredient |
| 04/13/2006 | WO2006038041A1 Besylate salts of six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain |
| 04/13/2006 | WO2006037335A2 Use of compounds for the prevention of drug-induced cell toxicity |
| 04/13/2006 | WO2006031556A3 Amidine substituted aryl aniline compounds |
| 04/13/2006 | WO2006024770A3 Phosphole derivatives complexed with metals, and pharmaceutical uses thereof |
| 04/13/2006 | US20060079713 Novel salt forms of poorly soluble probucol esters and ethers |
| 04/13/2006 | US20060079692 Synthesis of indole thiazole compounds as ligands for the Ah receptor |
| 04/13/2006 | US20060079688 Process for producing acid adduct salt of polyacidic base compound |
| 04/13/2006 | US20060079577 Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases |
| 04/13/2006 | US20060079575 Anticancer agent for drug resistant cancer |
| 04/13/2006 | US20060079572 Novel bioactive substance |
| 04/13/2006 | US20060079563 Cyclic protein tyrosine kinase inhibitors |
| 04/13/2006 | US20060079560 Crystalline form of omeprazole |
| 04/13/2006 | US20060079551 Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors |
| 04/13/2006 | US20060079550 Amino acid derivatives useful for the treatment of alzheimer's disease |
| 04/13/2006 | US20060079548 Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use |
| 04/13/2006 | US20060079539 Synergistic combination |
| 04/13/2006 | US20060079527 Compounds such as 1-[4-(3,4-difluoro-phenyl) -piperazin-1 -yl]-3-{methyl-[2-(9H-xanthen-9-yl)-ethyl]-amino}-propan-1 -one in free base or acid addition salt form, for therapy of depression, anxiety and bipolar disorders |
| 04/13/2006 | US20060079503 Thiazolidinones and the use therof as polo-like kinase inhibitors |
| 04/13/2006 | US20060079489 Lactose-free, non-hygroscopic and anhydrous pharmaceutical compositions of descarboethoxyloratadine |
| 04/13/2006 | US20060079484 Antithrombotic effect |
| 04/13/2006 | US20060079451 Heparin-binding proteins modified with sugar chains, method of producing the same and pharmaceutical compositions containing same |
| 04/13/2006 | US20060078975 Crystal structure of enzyme and uses thereof |
| 04/13/2006 | US20060078956 Methods to identify compounds that modulate rage |
| 04/13/2006 | US20060078940 21132, a human G-protein coupled receptor family member and uses therefor |
| 04/13/2006 | US20060078582 Use of compositions for treating rosacea |
| 04/13/2006 | US20060078568 Use of the residues from wine production |
| 04/13/2006 | US20060078552 Hybrid and single chain meganucleases and use thereof |
| 04/13/2006 | US20060078543 Neural progenitor cells derived from embryonic stem cells |
| 04/13/2006 | US20060078504 Sustanined-release pharmaceutical composition for lung administration |
| 04/13/2006 | CA2583431A1 Variant amyloid protein |
| 04/13/2006 | CA2583326A1 Receptor function regulating agent |
| 04/13/2006 | CA2583312A1 Process for the preparation of amorphous fluvastatin sodium |
| 04/13/2006 | CA2582615A1 Pharmaceutical composition for treatment of tear and salivary fluid drying |
| 04/13/2006 | CA2582327A1 2-arylcarboxamide-nitrogeneous heterocycle compound |
| 04/13/2006 | CA2581489A1 Use of compounds for the prevention of drug-induced cell toxicity |
| 04/12/2006 | EP1645634A2 Transgenic animal models for cardiac hypertrophy and uses thereof |
| 04/12/2006 | EP1645624A1 Nerve cells obtained by electrical pulse treatment es cell |
| 04/12/2006 | EP1645566A2 Analogs of parathyroid hormone |
| 04/12/2006 | EP1645558A1 Piperazinylpyrazines as serotonin 5-HT2C receptor modulators |
| 04/12/2006 | EP1645557A1 Novel substance having alpha-glucosidase inhibiting activity and food containing the same |
| 04/12/2006 | EP1645267A2 Method for producing an active ingredient concentrate and active ingredient concentrate |
| 04/12/2006 | EP1644490A2 Transgenic cells |
| 04/12/2006 | EP1476444B1 Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy |
| 04/12/2006 | EP1423436B1 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids |
| 04/12/2006 | EP1404174A4 Anti-infective compositions for treating disordered tissue such as cold sores |
| 04/12/2006 | EP1401828B1 N-formyl hydroxylamine compounds as inhibitors of pdf |
| 04/12/2006 | EP1358183B1 Cysteine protease inhibitors |
| 04/12/2006 | EP1345920B1 Novel sulfamides and their use as endothelin receptor antagonists |
| 04/12/2006 | EP1343771B1 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen c-proteinase inhibitors |
| 04/12/2006 | EP1331940B1 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 04/12/2006 | EP1317272B1 Composition for improving the cell protection comprising a lipophilic antioxidant an a hydrophilic antioxidant |
| 04/12/2006 | EP1299089B1 Drug delivery system for poorly water soluble drugs |
| 04/12/2006 | EP1294394B1 A COMBINATION PRODUCT COMPRISING MELAGATRAN AND A FACTOR Xa INHIBITOR |
| 04/12/2006 | EP1254119B1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 04/12/2006 | EP1207873A4 Methods of inhibiting osteoclast activity |
| 04/12/2006 | EP1200040B1 Two-component composition for cosmetic or pharmaceutical use |
| 04/12/2006 | EP1194156B1 Dietary supplement for treating malignancies and viral infections and improving immune function |
| 04/12/2006 | EP1192247B1 Sphingosine kinase enzyme |
| 04/12/2006 | EP1140175B1 Antibodies to truncated vegf-d and uses thereof |
| 04/12/2006 | EP1087981B1 Prenyl transferase inhibitors |
| 04/12/2006 | EP1071431B1 Cosmetic formulations comprising bis(triorganosilyl)hydroxycarboxylic acid derivatives |